Why Is ATAI Stock Soaring 59% After-Hours?

• The report indicates a possible announcement could come as soon as this week. 
• Lilly is negotiating a deal at a premium, the report said.
• Lilly has been ramping up its neuroscience segment through acquisitions, including the buyout of Centessa earlier this year.

Shares of AtaiBeckley Inc (ATAI) jumped 59% after-hours following reports that pharmaceutical giant Eli Lilly is close to a deal for the psychedelic drug developer.

Eli Lilly (LLY) is nearing an agreement involving AtaiBeckley, Bloomberg reported on Wednesday, citing people familiar with the matter. The report indicated that a possible announcement could come as soon as this week, though specific terms such as deal value, structure, or which asset is central were not disclosed.

However, Lilly is negotiating a deal at a premium, the report said.

ATAI’s Pipeline

This comes amid earlier speculation in 2026 that AtaiBeckley was exploring strategic options, including a potential sale or partnership for its lead program, with the company previously aiming for a multibillion-dollar valuation in talks.

AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting, durable mental health treatments using psychedelic compounds and related neuroplastogens. The company was formed through the combination of Atai Life Sciences and Beckley Psytech, creating a focused player in interventional psychiatry. The company is backed by billionaire Peter Thiel.

Its lead asset, the nasal spray BPL-003, is in late-stage development for treatment-resistant depression and holds FDA Breakthrough Therapy Designation. Topline results from the mid-stage trial of VLS-01 in TRD are expected in Q4 2026, and the company plans to advance it into a late-stage trial for major depressive disorder. The pipeline also includes EMP-01 under evaluation for social anxiety disorder.

Eli Lilly’s neuroscience segment, meanwhile, remains a smaller but strategically growing part of its business, generating around $1.39 billion in revenue in 2025. Growth is increasingly driven by Kisunla, its Alzheimer’s treatment, which contributed $249 million in sales for the full year 2025. Lilly is actively building its neuroscience presence through major deals, including the $6.3 billion acquisition of Centessa Pharmaceuticals, completed last month. Centessa‘s pipeline was focused on narcolepsy and other sleep-wake disorders.

Policy Support For Psychedelics

The potential deal comes on the heels of President Donald Trump signing an executive order in April to accelerate the development of psychedelic medicines for serious mental illnesses. The FDA also recently granted Compass Pathways’ synthetic psilocybin a national priority voucher for treatment-resistant depression. These vouchers are aimed at allowing for speedy reviews once an application is submitted to the FDA and increases the chances for an FDA psychedelic drug approval as early as late 2026.

How Did ATAI Retail Traders React?

On Stocktwits, retail sentiment around ATAI stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.

A Stocktwits user wrote, “A transaction, if completed, would represent one of the largest acquisitions in the psychedelic medicine sector and would signal major pharmaceutical validation of the field.”

“This deal should put ATAI on the map across the Globe,” another user said.

ATAI stock has gained 31% year-to-date. 

Read More: ASTS Stock Drops 13% After-Hours As Dilution Fears Hit On New Debt Raise

For updates and corrections, email newsroom[at]stocktwits[dot]com.